Search

Binoy Appukuttan

from Portland, OR
Age ~50

Binoy Appukuttan Phones & Addresses

  • 6030 SE 18Th Ave, Portland, OR 97202
  • 1115 Gibbs St, Portland, OR 97201
  • Pasadena, CA

Publications

Us Patents

Human Soluble Neuropilin-1 Primary Polyadenylation Signal And Uses Thereof

View page
US Patent:
7557197, Jul 7, 2009
Filed:
Jan 28, 2005
Appl. No.:
11/046219
Inventors:
J. Timothy Stout - Portland OR,
Trevor McFarland - Portland OR,
Peter J. Francis - Weybridge,
Binoy Appukuttan - Portland OR,
Assignee:
Oregon Health & Science University - Portland OR
International Classification:
C07H 21/02
C12N 15/00
A01N 43/04
US Classification:
536 231, 435455, 514 44
Abstract:
The human soluble neuropilin-1 (sNRP) polyadenylation signal (sNRP-poly(A)), situated downstream of the GT splice donor site of intron 12 of the full-length neuropilin-1 gene, also functions as the termination codon for sNRP. This 17 nucleotide sequence efficiently facilitates addition of poly(A) tails to RNAs expressed in cells. The present invention shows that this optimally succinct sequence has similar activity to the SV40 polyadenylation signal that is currently used in expression vectors. By using this shorter dual termination/polyadenylation signal and avoiding the need for large and cumbersome polyadenylation signals, expression vectors may be engineered to carry considerably larger genes.

Lentiviral Vector-Mediated Gene Transfer And Uses Thereof

View page
US Patent:
2002011, Aug 22, 2002
Filed:
Dec 19, 2001
Appl. No.:
10/025264
Inventors:
Binoy Appukuttan - Portland OR,
J. Stout - Portland OR,
International Classification:
A61K048/00
C12N015/861
US Classification:
424/093200, 514/044000, 435/456000
Abstract:
The present invention provides a means of human gene therapy for inherited or acquired proliferative ocular disease. It furnishes methods to exploit the ability of lentiviral vectors to transduce both mitotically active and inactive cells so that eye diseases may be treated.

Lentiviral Vector-Mediated Gene Transfer And Uses Thereof

View page
US Patent:
2003008, May 1, 2003
Filed:
Sep 17, 2002
Appl. No.:
10/245050
Inventors:
Binoy Appukuttan - Portland OR,
J. Stout - Portland OR,
International Classification:
A61K048/00
US Classification:
424/093210, 514/044000
Abstract:
The present invention provides lentiviral vectors that are useful in human gene therapy for inherited or acquired proliferative ocular disease. It furnishes methods to exploit the ability of lentiviral vectors to transduce both mitotically active and inactive cells so that eye diseases may be treated.

Lentiviral Vector-Mediated Gene Transfer And Uses Thereof

View page
US Patent:
2006006, Mar 23, 2006
Filed:
Sep 15, 2005
Appl. No.:
11/227319
Inventors:
J. Stout - Portland OR,
Binoy Appukuttan - Portland OR,
International Classification:
A61K 48/00
US Classification:
424093200
Abstract:
The present invention provides lentiviral vectors that are useful in human gene therapy for inherited or acquired proliferative ocular disease. It furnishes methods to exploit the ability of lentiviral vectors to transduce both mitotically active and inactive cells so that eye diseases may be treated.

Rtef-1 Variants And The Use Thereof For Inhibition Of Angiogenesis

View page
US Patent:
2009011, May 7, 2009
Filed:
Jun 6, 2008
Appl. No.:
12/134626
Inventors:
J. Timothy Stout - Portland OR,
Trevor J. McFarland - Portland OR,
Binoy Appukuttan - Portland OR,
International Classification:
A61K 48/00
C12N 15/12
C07K 14/47
C12N 15/85
A61K 31/711
A61K 38/17
A61K 39/395
A61K 35/76
A61P 35/00
A61P 35/04
A61P 27/02
C12N 15/861
C12N 15/869
C12N 15/867
C12N 15/86
US Classification:
4241391, 536 235, 514350, 4353201, 514 44, 514 12, 424 932
Abstract:
Dominant negative (DN) variants of transcriptional enhancer factor 1-related (RTEF-1) are described. DN RTEF-1 polypeptides may be directly targeted to cells or delivered in nucleic acid expression vectors to alter cellular transcription. Methods for inhibiting VEGF production and thereby treating angiogenic disorders such as cancer are described. For example, in certain aspects, DN RTEF-1 may be used to treat angiogenic disorders of the eye such as age related macular degeneration (AMD).

Lentiviral Vector-Mediated Gene Transfer And Uses Thereof

View page
US Patent:
2009014, Jun 11, 2009
Filed:
Dec 4, 2008
Appl. No.:
12/328580
Inventors:
J. Timothy Stout - Portland OR,
Binoy Appukuttan - Portland OR,
Assignee:
Research Development Foundation - Carson City NV
International Classification:
C12N 15/63
US Classification:
4353201
Abstract:
The present invention provides lentiviral vectors that are useful in human gene therapy for inherited or acquired proliferative ocular disease. It furnishes methods to exploit the ability of lentiviral vectors to transduce both mitotically active and inactive cells so that eye diseases may be treated.

Rtef-1 Variants And Uses Thereof

View page
US Patent:
2012006, Mar 15, 2012
Filed:
Apr 19, 2011
Appl. No.:
13/089687
Inventors:
J. Timothy Stout - Portland OR,
Binoy Appukuttan - Portland OR,
Trevor McFarland - Portland OR,
Anna Dye - Portland OR,
International Classification:
A61K 51/00
C07K 19/00
C12N 15/12
C12N 15/85
C12N 15/86
C12N 15/869
C12N 15/867
C12N 15/861
C12N 15/863
A61K 9/127
A61K 38/17
A61K 31/7088
C12N 5/071
A61K 39/395
A61K 38/18
A61P 35/00
A61P 37/04
A61P 19/02
A61P 35/02
A61P 35/04
A61N 5/00
C07K 14/47
US Classification:
424 111, 530350, 5303873, 536 235, 4353201, 424450, 514 212, 514 44 R, 435375, 514 192, 514 133, 4241581, 514 91, 4241331, 600 1
Abstract:
Disclosed are variant RTEF-1 polypeptides having an RTEF-1 amino acid sequence with one or more internal deletions, wherein the polypeptides reduce VEGF promoter activity. Some of the RTEF-1 polypeptides include an amino acid sequence that is at least 80% identical to the contiguous amino acids of 1) amino acids 24 to 47 of SEQ ID NO:15 and 2) each of SEQ ID NOs:16 and 17, but does not comprise the contiguous amino acids of SEQ ID NOs:8, 9, 11, or 12. Also disclosed are nucleic acids encoding the variant RTEF-1 polypeptides of the present invention. Pharmaceutical compositions that include the polypeptides and nucleic acids of the present invention are also disclosed. Methods of inducing cell contact inhibition, regulating organ size, and reducing intracellular YAP activity are also set forth, as well as methods of treating hyperproliferative diseases such as cancer using the pharmaceutical compositions of the present invention.
Binoy Appukuttan from Portland, OR, age ~50 Get Report